Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision oncology biotech developing African population-specific cancer diagnostics; $25M Cancer Grand Challenges award with Roche partnership on The African Cancer Atlas in Ghana.
Yemaachi Biotechnology is a precision oncology company applying immunogenomics, bioinformatics, and AI to develop cancer diagnostics and treatments specifically calibrated for African and African-descent populations — addressing the critical gap in oncology research where most cancer data and therapies have been developed on predominantly European-ancestry patient populations, leaving African patients underserved by current diagnostic tools and treatment protocols. Founded and backed by Y Combinator, Yemaachi is based in Accra, Ghana and has raised $29+ million including a $25 million Cancer Grand Challenges award and a $3 million seed round led by V8 Capital.\n\nYemaachi's research platform combines the collection of cancer genomics data from African patients (building one of the largest African cancer biobanks) with AI analysis to identify genomic variants, immune signatures, and biomarkers specific to African populations. This enables the development of diagnostic tests calibrated for African-specific tumor biology and the identification of therapeutic targets that may differ from European-ancestry cancer drivers. The company launched the Sheba HPV Test in Ghana (cervical cancer screening) and is partnering with Roche on The African Cancer Atlas — a comprehensive genomic characterization of cancer across Africa.\n\nIn 2025, Yemaachi operates at the intersection of oncology research, diagnostics, and population genomics for an underserved market. Cancer is a growing health crisis across sub-Saharan Africa, where late-stage diagnosis is the norm due to limited screening infrastructure and the poor sensitivity of Western-developed tests on African patients. Yemaachi's approach — building African-specific cancer intelligence — positions the company as both a research institution and a commercial diagnostics provider. The 2025 strategy focuses on expanding the African Cancer Atlas partnership with Roche, launching additional HPV and cancer screening products across West Africa, and partnering with global pharma companies seeking to include African populations in clinical trials.
Oracle Corporation's healthcare IT division (rebranded Cerner, $28.3B acquisition 2022); #2 US hospital EHR, VA/DoD federal EHR program, OCI cloud migration + ambient clinical AI competing with Epic Systems.
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, revenue cycle management, and population health analytics to hospitals, health systems, physician practices, ambulatory clinics, and government health agencies globally — operating as the rebranded Cerner Corporation following Oracle's $28.3 billion acquisition of Cerner in June 2022, the largest acquisition in Oracle's history. Oracle Health's EHR platform (the Cerner Millennium clinical information system) powers clinical documentation, physician order entry, nursing workflows, medication administration, and patient care coordination for approximately 30% of US hospitals — making Oracle Health the second-largest EHR vendor in the US hospital market after Epic Systems. A major integration program is underway to migrate Cerner's clinical applications to Oracle Cloud Infrastructure (OCI), enabling Oracle Health to leverage Oracle's cloud scale, Oracle's AI capabilities (generative AI for clinical documentation, ambient listening for physician notes), and Oracle's database performance advantages for health record analytics. Oracle Corporation named Clay Magouyrk and Mike Sicilia as co-CEOs in 2025 (replacing Safra Catz), positioning Oracle Health's clinical platform to benefit from the next-generation Oracle leadership team's emphasis on cloud and AI transformation.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.